00000000nam##2200000za#4500
0019.687810
003CaOODSP
00520210624231138
007cr |||||||||||
008150407|2005||||xxc|||||o    f|0| 0 eng|d
020 |a0-662-41741-0
040 |aCaOODSP|beng
043 |an-cn---
0861 |aH82-2/2005E-PDF
1101 |aCanada. |bPatented Medicine Prices Review Board.
24510|aBudget impact analysis guidelines : |h[electronic resource]|bneeds assessment / |cPrepared by the Patented Medicine Review Board (PMPRB) under the provisions and conditions of the National Prescription Drug Utilization Information System (NPDUIS).
260 |aOttawa - Ontario : |bPatented Medicine Prices Review Board |c[2005].
300 |a58p.|bfigs., references, tables
500 |a"Analytical Study Series" Catalogue number and ISBN for the print version have been incorrectly copied in the PDF edition.
590 |a10-01-Supp|b2010-04-07
69007|aPrescription drugs|2gcpds
69007|aHealth insurance|2gcpds
77508|tLignes directrices portant sur l'incidence du prix d'un médicament sur les budgets des régimes d'assurance médicaments : |w(CaOODSP)9.632249
85640|ahttp://publications.gc.ca|qPDF|s4981 KB|uhttps://publications.gc.ca/collections/collection_2008/hc-sc/H82-2-2005E.pdf